• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24133 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2008     Andalusian Health Technology Assessment Area (AETSA) [HER2 in selecting candidates to treatment with Trastuzumab. Determining HER2 status in breast cancer women]
2008     Andalusian Health Technology Assessment Area (AETSA) [HER2 in selecting candidates to treatment with Trastuzumab. Determining HER2 status in breast cancer women.]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hepatitis C virus screening in hospitals]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Hepatitis B vaccination in Denmark]
2009     Committee for New Health Technology Assessment (CNHTA) [Heparin-Platelet Factor 4(PF4) antibody test]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Hemoperfusion with polymyxin-B for the treatment of sepsis of abdominal origin by gram negative microorganisms]
2010     Committee for New Health Technology Assessment (CNHTA) [Hemoperfusion with Polymyxin B immobilized fiber]
2013     Andalusian Health Technology Assessment Area (AETSA) [Hemodynamic monitoring techniques in the intensive care units]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Hemodilution and perioperative blood recovery]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Helping Hands - comparing short-term and sustained effects of strategies to improve nurses' adherence with hand hygiene prescriptions]
2009     Andalusian Health Technology Assessment Area (AETSA) [Helical tomotherapy. Current uses and utility]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Heart disease in children: can children be helped to cope with their illness through psychological support?]
1994     Basque Office for Health Technology Assessment (OSTEBA) [Healthy/asymptomatic patient preoperative evaluation]
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health Technology Assessment. Why? What? When? How?]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health technology assessment report on metal on metal hip resurfacing versus total hip replacement]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (gastric cancer - GC)]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (ESCC - first-line treatment)
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health technology assessment perspectives on prescription writing]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Health Technology Assessment on diagnostic testing: Cardiac MRI and MRSA genetic testing (Real-time polymerase chain reaction)]
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health technology assessment of low stimulation IVF compared with standard IVF]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Health Technology Assessment of laparoscopic compared to conventional surgery with and without mesh for incisional hernia repair regarding safety, efficacy and cost-effectiveness]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Health Technology Assessment of laparoscopic compared to conventional surgery with and without mesh for incisional hernia repair regarding safety, efficacy and cost-effectiveness]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health technology assessment of erlotnib (Tarceva) for palliative treatment of non-small cell lung cancer]
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health technology assessment of endovascular coil treatment of intracranial aneurysms]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health technology assessment of a program for tertiary prevention of osteoporosis in patients with hip fracture]
2018     Andalusian Health Technology Assessment Area (AETSA) [Health technology assessment network in the SSPA. Methodology and work procedures]
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health technology assessment handbook]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Health technology assessment framework: adaptation for digital health technology assessment]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [Health technology assessment for the effectiveness and safety of human placenta injections]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Health promotion. Some theories and tools for planning and assessing lifestyle interventions]
2009     Basque Office for Health Technology Assessment (OSTEBA) [Health impact assessment of the Integral Regeneration Plan of Uretamendi-Betolaza and beltway]
2006     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Health economics modelling: costs, effectiveness and cost-effectiveness of biological agents in rheumatoid arthritis with particular emphasis on infliximab (REMICADE) therapy]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments]
2006     Center for Medical Technology Assessment (CMT) [Health economic evaluation of two methods for post-operative pain treatment after abdominal operation]
2021     Center for Drug Evaluation (CDE) [Health economic evaluation of three listed anti-cancer medications]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health economic analysis of diagnostic strategies of colorectal cancer - a health technology assessment]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Health centre major surgery in Osakidetza - Basque Health Service]
2008     Health Council of the Netherlands Gezondheidsraad (GR) [Health care for the elderly with multimorbidity]
2003     Basque Office for Health Technology Assessment (OSTEBA) [Health care for terminal patients: systematic review and analysis of health care in hospitals of the Basque Country]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Health care efficiency and cost-efficacy of rapid diagnostic testing of methicillin-resistant Staphylococcus aureus]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Health and health services use in immigrant and native population in Spain]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [HD Analyzer® in cataract and dry eye]
2011     Committee for New Health Technology Assessment (CNHTA) [HBV entecavir resistance mutation [PCR-RFMP]]
2010     Committee for New Health Technology Assessment (CNHTA) [HBV drug resistance mutation[multiplex-PCR]]
2010     Committee for New Health Technology Assessment (CNHTA) [HBB(beta-hemoglobin)gene deletion Test[MLPA]]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Haploidentical bone marrow transplantation in patients with blood cancers]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [Handbook for clinical practice guideline developer]
2010     Committee for New Health Technology Assessment (CNHTA) [Hand transplantation]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Halcyon intensity-modulated beam conformal image-guided volumetric radiotherapy system for oncology treatment]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Hair micro transplant using follicular unit extraction technique for alopecia]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Hadrontherapy in the treatment of cancer]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hadron therapy: proton and carbon ion therapy - a review of clinical evidence of efficacy, ongoing research and reimbursement]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hadron therapy in children: evidence synthesis for 15 paediatric tumours. Report based on Belgian (KCE) HTA report]
2002     The Netherlands Organisation for Health Research and Development (ZonMw) [Gynecological cancer: diagnostic value of radiological tests]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Addendum to Commission A17-60]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides for the pharmacological treatment of STBBIs]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: wound care-assessment, management, and optimal treatment use]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: use of electrodiagnostic testing in the neurological investigation - electromyography and nerve conduction studies]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urinary tract infection in people aged 14 and over - diagnostic guidelines, optimal use of 1st- and 2nd-line treatments and follow-up ]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urethral discharge - diagnostic measures and pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD-L1]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the optimal usage guide on sexually transmitted and blood borne infections – confirmed Mycoplasma genitalium infection]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: unusual vaginal discharge - diagnostic measures and pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: type 2 diabetes screening and cardiovascular risk assessment]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: the management of myalgic encephalomyelitis / chronic fatigue syndrome]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: syndromic approach - pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: relevance of preoperative consultation and testing for low-risk elective surgery in people aged 16 and over]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Quality indicators for the care and services provided in long-term left ventricular assist device implantation programs]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of immunoglobulin in fertility, cardiology and other indications]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of echocardiography in Québec- diagnosis and follow-up of chronic heart failure]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of cardiac ultrasound in Québec - diagnosing patients with a murmur and monitoring patients with valve diseases (native and prosthetic valves)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: methodological report in support of the reflection guide supporting clinical and organizational practices in rehabilitation services for young people with adjustment problems aged 10 or older]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: measurement and monitoring of total serum bilirubin in a newborn with signs suggestive of neonatal jaundice]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: major depressive disorder during pregnancy]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: judicious blood culture use]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intravenous iron therapy in adults]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intra-abdominal infections in adults]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating osteodensitometry following the assessment of fracture risk with the FRAX tool]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiate diagnostic measures in the presence of symptoms and signs suggestive of urinary tract infection (cystitis and pyelonephritis) and initiate first-line pharmacological treatment for cystitis in an individual 14 years of age and older]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: hormone therapy for the management of the clinical manifestations of menopause]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: helicobacter pylori - diagnosis, optimal treatment and follow-up]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: gradual return to activities following a mild traumatic brain injury or concussion (MTBI/concussion)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: genital herpes - identification, diagnosis, optimal use of antivirals and follow-up]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: delirium in elderly persons in emergency departments - prevention, assessment and management]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: COVID-19 - optimal use of parmacological treatments]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: confirmed chlamydia trachomatis or neisseria gonorrhoeae infection]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: chronic obstructive pulmonary disease- detection, diagnosis, optimal use of medications and inhalation devices, and global management]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: care management for youth under 18 with attention deficit hyperactivity disorder (ADHD)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: asthma management in children and adults]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: adjustment of antidepressants for the follow-up of a major depressive disorder or an anxiety disorder]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Acute myeloid leukemia treatment algorithm]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: acute exacerbation of chronic obstructive pulmonary disease -diagnostic approach, optimal use of treatments, and follow-up]